News

SCCS Raises Safety Concerns Over Phytonadione Epoxide (Vitamin K1 Oxide) in Cosmetics

The European Union’s Scientific Committee on Consumer Safety (SCCS) has published its preliminary scientific advice on the safety of Phytonadione Epoxide (Vitamin K1 Oxide) in cosmetic products, concluding that the ingredient cannot be considered safe at concentrations of up to 1%. 

Published on 5 November 2026, the preliminary opinion (SCCS/1690/26) highlights serious concerns regarding allergic skin reactions, insufficient quantitative toxicological data and the absence of adequate mutagenicity and genotoxicity information. 

The Committee was unable to establish a safe maximum concentration for Phytonadione Epoxide in cosmetic products due to significant gaps in the available scientific evidence. 

The preliminary scientific advice was adopted on 4 November 2026 and remains open for comments until 11 January 2027. 

These findings are particularly relevant to cosmetic manufacturers, ingredient suppliers and Responsible Persons placing products containing Vitamin K1 Oxide on the European Union market. 

What Is Phytonadione Epoxide (Vitamin K1 Oxide)? 

Phytonadione Epoxide (CAS No. 25486-55-9, EC No. 247-022-9) is an oxidised form of Vitamin K1 (Phytonadione). 

The substance may occur naturally or be produced synthetically and is structurally related to Vitamin K1. 

In cosmetic products, Phytonadione Epoxide is primarily used as a skin-conditioning ingredient. 

It may be found in products marketed for improving the appearance of the skin, including: 

  • Eye contour creams. 
  • Under-eye skincare products. 
  • Anti-ageing serums. 
  • Formulations intended to reduce the appearance of redness. 
  • Skincare products targeting uneven skin tone. 

However, the intended cosmetic function of an ingredient does not independently demonstrate its safety under the relevant conditions of use. 

Why Has the SCCS Raised Safety Concerns? 

The SCCS evaluated Phytonadione Epoxide at the request of the European Commission, considering the available toxicological information, published scientific literature and reported undesirable effects. 

Three main issues were identified: 

  1. Evidence of serious allergic skin reactions associated with the ingredient. 
  1. Insufficient quantitative information to establish safe exposure levels, particularly for skin sensitisation. 
  1. A lack of adequate mutagenicity and genotoxicity data. 

These limitations prevented the Committee from completing a comprehensive safety assessment. 

Is Phytonadione Epoxide Safe at Concentrations up to 1%? 

No. The SCCS concluded that Phytonadione Epoxide cannot be considered safe when used in cosmetic products at concentrations up to 1%. 

The European Commission requested a scientific assessment of the ingredient’s safety at a maximum proposed concentration of 1%. 

Based on the information available, the SCCS did not reach a favourable safety conclusion for this concentration. 

The Committee identified several published case reports and serious undesirable effects indicating that Phytonadione Epoxide may cause severe allergic skin reactions requiring medical treatment. 

Importantly, 1% should not be interpreted as an authorised, established or scientifically supported safe concentration. 

The Committee was also unable to identify an alternative maximum concentration that could be considered safe. 

Allergic Contact Dermatitis and Skin Sensitisation Risks 

One of the most significant findings of the SCCS assessment concerns allergic contact dermatitis (ACD) and skin sensitisation. 

Allergic contact dermatitis is an inflammatory skin reaction that may develop following sensitisation to a particular substance. 

Clinical symptoms may include redness, itching, swelling and other dermatological reactions. 

The SCCS highlighted evidence from published case reports and serious undesirable effect (SUE) notifications demonstrating that Phytonadione Epoxide can cause serious allergic skin reactions, sometimes requiring medical intervention. 

These findings are particularly relevant to cosmetic products applied to sensitive areas, including the skin around the eyes. 

Relationship Between Vitamin K1 and Vitamin K1 Oxide 

Phytonadione Epoxide is structurally related to Vitamin K1, although they are distinct chemical substances. 

Vitamin K1 has previously been prohibited in cosmetic products in the European Union following concerns relating to allergic contact dermatitis. 

Subsequent reports of allergic reactions associated with Phytonadione Epoxide have raised additional concerns about the safety of the oxidised form. 

Nevertheless, the regulatory status and scientific evaluation of each substance must be considered separately. 

Why Could the SCCS Not Establish a Safe Maximum Concentration? 

The SCCS identified insufficient quantitative data to derive a Point of Departure (PoD) for relevant toxicological hazards. 

A Point of Departure is a reference value used in toxicological risk assessment to support the evaluation of exposure and potential adverse effects. 

For Phytonadione Epoxide, the available evidence was insufficient to establish an appropriate PoD, particularly for skin sensitisation. 

The Committee also identified inadequate information about consumer exposure through cosmetic products. 

Without sufficient hazard and exposure data, a complete safety assessment could not be performed. 

As a result, the SCCS was unable to determine a safe maximum concentration for the ingredient. 

Mutagenicity and Genotoxicity: What Data Are Missing? 

The preliminary SCCS opinion also identifies significant gaps in the available information concerning mutagenicity and genotoxicity. 

Mutagenicity refers to the potential of a substance to cause permanent changes in genetic material. 

Genotoxicity is a broader concept covering damage to DNA and other components of the genetic system. 

The SCCS noted that no relevant mutagenicity or genotoxicity data had been provided during the call for data or identified in the published scientific literature. 

Consequently, the Committee concluded that the potential mutagenic and genotoxic effects of Phytonadione Epoxide cannot be excluded without appropriate experimental evidence. 

This does not mean that the ingredient has been demonstrated to be mutagenic or genotoxic. 

Rather, the available information is insufficient to rule out these potential hazards. 

What Is the Status of the SCCS Scientific Opinion? 

The document published on 5 November 2026 is a preliminary scientific opinion, not a final SCCS opinion. 

Preliminary opinions provide the Committee’s scientific assessment based on the available information and are opened for a defined comment period. 

Comments may address the interpretation, evaluation or incorporation of the submitted scientific evidence. 

Following the review of comments, the SCCS may proceed with finalising its scientific advice. 

Public Comment Deadline: 11 January 2027 

The commenting period for Phytonadione Epoxide will close on 11 January 2027. 

The process is intended to allow clarifications and comments concerning the existing preliminary assessment. 

It should not be confused with a general invitation to submit an entirely new scientific dossier. 

Implications for EU Cosmetics Regulation 

Cosmetic products placed on the European Union market are subject to Regulation (EC) No 1223/2009, which establishes requirements concerning cosmetic product safety, ingredients and the obligations of Responsible Persons. 

The SCCS preliminary opinion provides scientific information that may inform subsequent regulatory decisions by the European Commission. 

However, the publication of an SCCS preliminary opinion does not automatically introduce a new legal prohibition or maximum concentration limit. 

Any further regulatory measures would require the relevant procedures under the EU cosmetics legislative framework. 

Manufacturers should therefore distinguish between the scientific safety findings and any subsequent legally binding regulatory requirements. 

What Should Cosmetic Manufacturers and Responsible Persons Do? 

The SCCS preliminary findings highlight the importance of reviewing formulations containing Phytonadione Epoxide. 

Relevant actions for cosmetic businesses include: 

  1. Review product formulations: Identify cosmetic products containing Phytonadione Epoxide. 
  1. Assess ingredient concentrations: Verify current usage levels and intended product applications. 
  1. Examine supporting safety data: Review supplier documentation and available toxicological information. 
  1. Evaluate skin sensitisation risks: Consider reported allergic reactions and relevant scientific evidence. 
  1. Review undesirable effect reports: Examine available consumer complaints and serious undesirable effect records. 
  1. Reassess Cosmetic Product Safety Reports: Determine whether existing CPSRs adequately address the identified safety concerns. 
  1. Monitor regulatory developments: Follow the final SCCS opinion and any subsequent European Commission measures. 

Given the current assessment, using the ingredient at a concentration below 1% should not automatically be considered sufficient evidence of safety. 

What Does the SCCS Opinion Mean for Vitamin K1 Oxide in Cosmetics? 

The preliminary SCCS scientific advice published on 5 November 2026 raises significant concerns about the safety of Phytonadione Epoxide (Vitamin K1 Oxide) in cosmetic products. 

The Committee did not consider the ingredient safe at concentrations of up to 1% and could not establish an alternative safe maximum concentration. 

The assessment highlights serious allergic skin reactions, insufficient information concerning skin sensitisation and consumer exposure, and unresolved data gaps relating to mutagenicity and genotoxicity. 

The scientific advice remains preliminary, with comments accepted until 11 January 2027. 

Cosmetic manufacturers, ingredient suppliers and Responsible Persons should carefully review the ingredient’s use, available safety documentation and potential implications for product safety assessments. 

Need Support with EU Cosmetic Ingredient Safety Compliance? 

Obelis Türkiye supports cosmetic companies in reviewing ingredient safety, assessing product formulations, preparing Cosmetic Product Safety Reports (CPSRs) and navigating EU regulatory compliance requirements. 

For further information, tailored regulatory support or a quotation, contact us through our website or connect with us on LinkedIn and Instagram.